AbbVie’s venetoclax Phase 2 trial meets principal endpoint in sufferers with relapsed/refractory CLL with 17P deletion AbbVie , a worldwide biopharmaceutical business, today announced that a Phase 2 trial of its investigational medicine venetoclax met its main endpoint of achieving overall response rates in individuals with relapsed/refractory or previously untreated chronic lymphocytic leukemia with 17p deletion, according to an unbiased review analysis. The open-label study evaluated the efficacy and safety of venetoclax, an inhibitor of the B-cell lymphoma-2 protein that is being developed together with Genentech and Roche. Data out of this research will be offered at an upcoming medical conference and will serve as the pivotal registration data for applications to the FDA, EMA and various other health authorities.Also in Mechanical Engineering at the University of California Santa Barbara in 1995 and 1999, respectively. In 1999, he received a Whitaker Postdoctoral Fellowship to join the Beckman Laser beam Institute and the former Department of Chemical and Biochemical Engineering and Materials Sciences at the University of California Irvine . Since 2003 Prof. Aguilar joined the Section of Mechanical Engineering at University of California Riverside , where he was promoted to Associate Professor in 2007 and Full Professor in 2012. Prof. Aguilar served as the Graduate Advisor and Chair of the Graduate Committee of the ME Section from 2005-2010 and 2011-2012 and presently serves as the Section Chair.